GlassScriptPhysician profile
Lawrence E Vallario
NPI 1710084199
$5,486.17
in general payments reported to CMS, 2019-2025
32 companies · $601 in 2025
The $601 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $664 · 2021: $858 · 2022: $1,217 · 2023: $1,100 · 2024: $151 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $721.63 | 2022-2023 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $500.15 | 2021-2025 | Verquvo, Belsomra |
| Amgen INC. | $483.23 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $476.92 | 2019-2025 | |
| Abbott Laboratories | $371.28 | 2019-2024 | Mitraclip, Aveir, Cardiomems |
| Amarin Pharma, INC. | $354.58 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $297.34 | 2019 | |
| Astellas Pharma US INC | $292.60 | 2019-2022 | |
| Pfizer INC. | $257.12 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $241.64 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.13 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $216.98 | 2019-2023 | Xarelto |
| Impulse Dynamics (USA) INC. | $171.81 | 2022-2023 | Optimizer |
| Esperion Therapeutics, INC. | $166.89 | 2020-2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $88.79 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $77.22 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $74.36 | 2020-2025 | Wainua, Farxiga, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.57 | 2020-2025 | Lifevest |
| Edwards Lifesciences Corporation | $49.06 | 2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Alnylam Pharmaceuticals INC. | $48.42 | 2025 | Amvuttra |
| Abiomed | $37.71 | 2021 | |
| Daiichi Sankyo INC. | $34.37 | 2022-2023 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $30.90 | 2025 | Opsynvi, Uptravi |
| Novo Nordisk INC | $30.50 | 2023 | Ozempic |
| Bardy Diagnostics, INC. | $27.50 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $24.62 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.60 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $20.18 | 2023 | Inpefa |
| Philips North America LLC | $18.86 | 2025 | Event |
| Chiesi USA, INC. | $16.39 | 2025 | Juxtapid |
| Baxter Healthcare | $15.36 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Coala Life INC | $10.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Vallario listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.